Indirect comparison of continuous and time‑limited BTKi–venetoclax in TP53 ‑wild‑type CLL: does IGHV still matter?

Leukemia & lymphoma/Leukemia and lymphoma 2026 Open access

Read full text
Authors: S Molica, Diana Giannarelli, David John Allsup
DOI: 10.1080/10428194.2026.2637862
Cited by: 1
References: 16

Abstract

To the EditorIn chronic lymphocytic leukemia (CLL) with wild-type TP53, immunoglobulin heavy chain variable region (IGHV) mutation status is a robust prognostic marker that stratifies long-term cli...

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Publisher
Informa UK Limited
Volume
67
Issue
7
Pages
1642–1645
Publication date
4 March 2026
Language
EN